Potentiation of cancer immunogenicity by targeting PARP

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are approved for treating tumors with homologous recombination repair defects.
• Tumor cells with DNA repair defects may be susceptible to PARPi-induced immunogenic cell death (ICD).

Purpose of the Study:

• To investigate the potential of PARP inhibitors (PARPi) to induce immunogenic cell death (ICD) and enhance anti-tumor immunity.
• To explore the role of PARPi in overcoming immunotherapy resistance by modulating the tumor immune microenvironment.

Main Methods:

• The study focuses on the mechanism by which PARPi induce tumor cell death and its impact on immune cell recognition.
• Analysis of tumor neoantigen generation and reprogramming of the tumor immune microenvironment.

Main Results:

• PARPi were shown to induce tumor cell death that enhances immune cell recognition and attack.
• PARPi promote increased tumor neoantigen generation and reprogram the tumor immune microenvironment towards an immunostimulatory state.
• PARPi alleviate intratumoral effector T cell immune dysfunction, particularly in immunotherapy-resistant contexts.

Conclusions:

• The relationship between PARPi-induced ICD and enhanced anti-tumor immunity suggests PARPi can sensitize tumors to immunotherapy.
• Combinatorial approaches using PARPi with immune checkpoint inhibitors or cancer vaccines may improve efficacy against solid tumors and promote host-protective anti-tumor immune control.